Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR 42.06
-0.80 (-1.86%)
May 13, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
2.00
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
88.18B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 23.14B |
| Fresenius SE & Co. KGaA | 22.13B |
| Bayer Aktiengesellschaft | 46.61B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.33B |
Bristol-Myers Squibb Company News
- 3 days ago - Bristol-Myers Squibb (BMY) and Sanofi Settle Plavix Lawsuit for $700M - GuruFocus
- 3 days ago - Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit - Seeking Alpha
- 5 days ago - A Look Into Bristol-Myers Squibb Inc's Price Over Earnings - Benzinga
- 6 days ago - 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Benzinga
- 7 days ago - Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Wallstreet:Online
- 11 days ago - FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Benzinga
- 16 days ago - Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates - GuruFocus
- 18 days ago - Trump pharma tariffs would raise U.S. drug costs by $51 billion annually, report finds - CNBC